This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-15 and is reviewed periodically as new material appears.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
One example at the tissue level showed the involvement of MC1R in the normal and pathological development of articular cartilage in the mouse knee. In this study the authors compared normal mice with mice completely lacking MC1R. Even without experimental induction of osteoarthritis, mice without MC1R had less articular cartilage (as shown by the red staining in the image). After experimental induction of osteoarthritis, the defect caused by MC1R was more pronounced.
=== Advocacy for children === In her role as spokesperson for Child Poverty Action Group, Turner commented in the media on the relationship between low income and poor child health, and in 2008 co-authored a research report which stated that poverty was causing "devastation" in the health sector, with data showing New Zealand children had "higher rates of preventable illness and deaths from injuries than children in almost any other OECD country". The report drew attention to the fact that Maori and Pasifika children were disproportionately affected by this. In 2012, Turner, as a member of the Children's Commissioner Expert Advisory Group on Solutions to Child Poverty, contributed to a major report that explored how child poverty in New Zealand could be reduced. Turner later said she was disappointed at the response by the New Zealand government and that they had only focussed on a few areas instead of taking a fully systemic approach to reducing child poverty. This report supported the findings in a previous paper, endorsed by the New Zealand Medical Association and co-authored by Turner, which contended that overcrowding, poor nutrition, exposure to tobacco and stress contributed to creating a social environment in which the population was vulnerable and likely to have less access to health care services.
Pillared graphene is a hybrid carbon structure, consisting of an oriented array of carbon nanotubes connected at each end to a sheet of graphene. It was first described theoretically by George Froudakis and colleagues at the University of Crete in Greece in 2008. Pillared graphene has not yet been synthesized in the laboratory, but it has been suggested that it may have useful electronic properties, or as a hydrogen storage material.
In January 2006, the United States Food and Drug Administration (FDA) announced that Elidel packaging would be required to carry a black box warning regarding the potential increased risk of lymph node or skin cancer, as for the similar drug tacrolimus, whereas current practice by UK dermatologists is not to consider this a significant real concern and they are increasingly recommending the use of such new drugs. Importantly, although the FDA has approved updated black-box warning for tacrolimus and pimecrolimus, the recent report of the American Academy of Dermatology Association Task Force finds that there is no causal proof that topical immunomodulators cause lymphoma or nonmelanoma skin cancer, and systemic immunosuppression after short-term or intermittent long-term topical application seems an unlikely mechanism. Another recent review of evidence concluded that postmarketing surveillance shows no evidence for this systemic immunosuppression or increased risk for any malignancy. A 2023 systematic review and meta-analysis published in The Lancet Child & Adolescent Health further concluded with moderate-certainty evidence that the two drugs were not associated with any increased risk of cancer. However, strong debates and controversies continue regarding the exact indications of immunomodulators and their duration of use in the absence of active controlled trials. Dermatologists' and allergists' professional societies, the American Academy of Dermatology, and the American Academy of Allergy, Asthma, and Immunology, have protested the inclusion of the black box warning.
Due to the arrangement of the receiver antennas, the sensitive area had a number of side lobes that allowed reception at multiple vertical angles. Typically the operator would use the upper set of antennas at 215 ft (66 m), which had the clearest view of the horizon. Due to the half-wave interference from the ground, the main lobe from this antenna was directed at about 2.5 degrees above the horizontal, with its sensitive region extending from about 1 to 3 degrees. At the ground the gain was zero, which allowed aircraft to escape detection by flying at low altitudes. The second lobe extended from about 6 to 12 degrees, and so on. This left a distinct gap in the reception pattern centred at about 5.2 degrees. This reception pattern provided CH with a relatively accurate way to estimate the altitude of the target. To do this, the motorized switch in the receiver hut was used to disconnect the four receiver masts and instead select the two vertically displaced antennas on one mast. When connected to the radiogoniometer, the output on the display was now effected by the relative signal strength of the two lobes, rather than the relative strengths in X and Y in the horizontal plane. The operator swung the radiogoniometer looking for the peak or minimum reception, as before, and noted the angle. The number reported by the operator was the line-of-sight range to the target, or slant range, which included components of both the horizontal distance and altitude.
Sources: en.wikipedia.org
=== Internal relationships === The phylogeny of the teleosts has been subject to long debate, without consensus on either their phylogeny or the timing of the emergence of the major groups before the application of modern DNA-based cladistic analysis. Near et al. (2012) explored the phylogeny and divergence times of every major lineage, analysing the DNA sequences of 9 unlinked genes in 232 species. They obtained well-resolved phylogenies with strong support for the nodes (so, the pattern of branching shown is likely to be correct). They calibrated (set actual values for) branching times in this tree from 36 reliable measurements of absolute time from the fossil record. The teleosts are divided into the major clades shown on the cladogram, with dates, following Near et al. More recent research divide the teleosts into two major groups: Eloposteoglossocephala (Elopomorpha + Osteoglossomorpha) and Clupeocephala (the rest of the teleosts).
=== Medication-specific === Due to the frequency of injections required for the administration of insulin products via subcutaneous injection, insulin is associated with the development of lipohypertrophy and lipoatrophy. This can lead to slower or incomplete absorption from the injection site. Rotating the injection site is the primary method of preventing changes in tissue structure from insulin administration. Heparin-based anticoagulants injected subcutaneously may cause hematoma and bruising around the injection site due to their anticoagulant effect. This includes heparin and low molecular weight heparin products such as enoxaparin. There is some low certainty evidence that administering the injection more slowly may decrease the pain from heparin injections, but not the risk of or extent of bruising. Subcutaneous heparin-based anticoagulation may also lead to necrosis of the surrounding skin or lesions, most commonly when injected in the abdomen. Many medications have the potential to cause local lesions or swelling due to the irritating effect the medications have on the skin and subcutaneous tissues. This includes medications such as apomorphine and hyaluronic acid injected as a filler, which may cause the area to appear bruised. Hyaluronic acid "bruising" may be treated using injections of hyaluronidase enzyme around the location. Other common medication-specific side effects include pain, burning or stinging, warmth, rash, flushing, or multiple of these reactions at the injection site, collectively termed "injection site reactions".
=== Environmental benefits === Hydroponic farming offers several environmental benefits when compared to traditional agriculture. The most significant of these is reduced water consumption and controlled nutrient usage. Hydroponic systems can use up to 90% less water when compared to conventional farming. Also, in hydroponic systems, water and nutrients are recirculated in a controlled environment, eliminating runoff and the discharge of pollutants into local waterways. By using hydroponics to grow crops indoors or in greenhouses, land use is minimized, reserving arable soil and land for other purposes. Also, utilizing the controlled environment created for hydroponic farming reduces the need for pesticides and other chemicals. This is due to the fact that many pests and diseases in farming are soil-borne. Since hydroponics uses other substrates, eliminating soil use, these farming obstacles are reduced. Using hydroponics systems that grow vertically in a space-efficient manner also makes cultivating crops in urban areas possible. However, These systems can use large amounts of energy due to the use of water filtration systems and artificial lighting. Due to this, the carbon footprint of a hydroponic farm can vary depending on factors like the energy source, local climate, and the scale of the operation. Using renewable energy sources such as solar panels has the possibility of making hydroponic farms more sustainable.
==== Vaginal dryness ==== In women with Sjögren's disease, vaginal dryness, vulvodynia, and dyspareunia (painful sexual intercourse) are often reported; personal lubricants are recommended to help lessen irritation or pain that may result from dryness in the vaginal and vulval areas.
In 1964, the first franchise was purchased by former police officer Kermit Bekke. This location, located at 1654 West Carson Street in Torrance, California, had its grand opening on May 28, 1965. Bekke sold his franchise a year and a half later. This location closed in 1975 when it moved across the street to store #1130 at 1619 West Carson Street, which itself would close in the late 1990s and subsequently be repurposed. On January 20, 1967, the 100th Taco Bell grand opening took place in Anaheim, located at 400 South Brookhurst (store #63); this location would later be replaced by a new location at 324 South Brookhurst in 1993. The first Taco Bell restaurant east of the Mississippi River (the 270th to open, store #258) opened at 2050 East Main Street in Springfield, Ohio, on September 20, 1968. Original Taco Bells featured only walk-up window service without indoor seating or drive-thru service. Inside seating was added sporadically in 1968 and drive-thru service was not generally available until 1980. As of 2025, seven original mission-style operating Taco Bell restaurants still remain, located in California and Colorado. A mission-style location (opened in April 1976) that operated in Honolulu, Hawaii (store #1281) remodeled in 2024, and another Mission-style location in Scottsdale, Arizona (store #31, opened circa July 3, 1966) closed on April 12, 2025.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.